Comparative study to evaluate efficacy and safety of azilsartan and telmisartan in patients with grade I-II essential hypertension

Abstract

INTRODUCTIONEssential hypertension is a common cardiovascular disorder with sustained increase in blood pressure ≥140/90 mmHg. The elevated arterial pressure causes pathological changes in the vasculature and hypertrophy of the left ventricle. Hypertension is the principle cause of stroke that is a major risk factor for coronary artery disease (CAD) and its attendant complications like myocardial infarction and sudden cardiac death. It is also a major contributor to cardiac failure, renal insufficiency and dissecting aneurysm of aorta. 1Hypertension is an increasingly prevalent chronic condition that is associated with serious morbidity and mortality. It is an important risk factor for the development and progression of cardiovascular disease (CVD), which is predicted to become the leading cause of death and disability worldwide by 2020.2 As per the Registrar General of India and Million Death Study investigators (2001)(2002)(2003), CVD was the largest cause of deaths in males (20.3%) as well as females (16.9%) and led to about 2 million deaths annually. In India, 23.10% men and 22.60% women over the age of 25 years suffer from hypertension. Treating systolic blood pressure (SBP) and diastolic blood pressure (DBP) to targets that are <140/90 mmHg is ABSTRACT Background: Objectives of the study was to study the effect of Azilsartan 40mg once daily versus Telmisartan 40mg once daily in patients with Grade I-II essential hypertension. Methods: A prospective study was conducted at MGM Medical college and Hospital which included 80 patients in each group with Grade I-II essential hypertension. The sex, age, presenting illness, and family history of the patients were recorded. Investigations such as blood sugar, urine analysis, kidney function test, lipid profile, and ECG were performed before starting the treatment. Any adverse effects during the treatment were noted. Blood pressure was recorded at baseline and during follow-up. One group received Azilsartan 40mg once daily and another group Telmisartan 40mg once daily. Patients were followed-up every week for 5 weeks. Results: Patients receiving Azilsartan 40mg and Telmisartan 40mg showed a significant fall (P <0.05) in systolic (SBP) at the end of fifth week, when compared to baseline and diastolic blood pressure (DBP) significant fall at fourth and fifth week. The difference in fall in SBP and DBP was insignificant between the groups, after first, second and third week (P >0.05). Adverse effects such as Nasopharyngitis, Upper respiratory tract inflammation, Gastroenteritis, headache, dizziness, and fatigue were reported with both drugs. Conclusions: Reduction of blood pressure with Azilsartan and Telmisartan was similar, but fall in blood pressure from baseline was highly significant in both groups.

An Effectiveness, Safety and Tolerability Study of Azilsartan and Telmisartan in Patients of Essential Hypertension : A Randomized and Open-Label Study

“…After giving the drug orally, the prodrug azilsartan medoxomil is rapidly converted into its active form azilsartan which blocks angiotensin induced AT1 receptor activation in insurmountable fashion. [15] In the present study which was conducted as monotherapy with Azilsartan and Telmisartan in patients of essential hypertension, it was observed that both the drugs were effective in reducing both the systolic as well as diastolic blood pressure during the 12weeks study period. When the drugs were compared for their effectiveness, it was seen that both azilsartan and telmisartan are equally effective in reducing the systolic and diastolic blood pressure.…”

“…In group 1(azilsartan), mean diastolic blood pressure at 0 week was 92.37±3. 15 week when compared with the baseline systolic blood pressure. The mean diastolic blood pressure was reduced by 9.86% at the end of the study period.…”

Sartans in the treatment of arterial hypertension: focus on telmisartan and azilsartan. A review

“…Вместе с тем в ряде других исследований снижение АД оказалось сопоставимо в группах телмисартана и азилсартана в эквипотентных дозах (рис. 3) [57][58][59][60]. Таким образом, основываясь на всех доступных данных, можно заключить, что азилсартан и телмисартан имеют сопоставимую антигипертензивную эффективность.…”